Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Generic Formulation Products

Generic Formulation Products

Generic Formulation Products

Finished Dosage Forms - Product List:

Download Brochure

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Therapy Area Product Name Oral Inj Strength Dossier Status Connect
Anti-Diabetic Linagliptin 5 mg Filed
Anti-Diabetic Sitagliptin HCL + Metformin 50 + 500, 50 + 850 Under Development
Anti-Diabetic Linagliptin + Metformin 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg Filed
Anti-Diabetic Sitagliptin HCL 25, 50, 100 mg Filed
Anti-Diabetic Sitagliptin Phosphate 25, 50 and 100 mg Filed
Anti-Diabetic Sitagliptin Phosphate + Metformin 50 + 500, 50 + 1000 mg Filed
Anti-Diabetic Liraglutide 6 mg/ml (3 ml) Under Development
Anti-Obesity Liraglutide 6 mg/ml (3 ml) Under Development
Cardiovascular Eltrombopag 12.5, 25, 50 and 75 mg Filed
Cardiovascular Bempedoic acid Ezetimibe 180 mg/10 mg Under Development
Cardiovascular Bempedoic acid 120 mg and 240 mg Under Development
Cardiovascular Edoxaban 15 mg, 30 mg and 60 mg Under Development
Cardiovascular Tafamidis Meglumine 20 mg Under Development
Cardiovascular Apixaban 2.5 mg and 5 mg Filed
Cardiovascular Dabigatran 75 mg, 110 mg and 150 mg Filed
Cardiovascular Rivaroxaban 10, 15 and 20 mg Filed
Cardiovascular Sacubitril/ Valsartan 24/26, 49/51, 97/103 mg Filed
Cardiovascular Ticagrelor 60 mg and 90 mg Filed
Cardiovascular Treprostinil 1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml) Filed
Cardiovascular Fondaparinux 2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml Filed
Central Nervous System Glatiramer 20 mg and 40 mg Filed
Central Nervous System Sugammadex 100 mg/ml (2 ml and 5 ml) Filed
Central Nervous System Vigabatrin USP 500 mg Filed
Central Nervous System Edaravone 60 mg/100 ml Filed
Central Nervous System Topiramate ER 25, 50, 100 and 200 mg Filed
Central Nervous System Carboprost USP Inj 250 mcg/ml PFS Filed
Central Nervous System Colchicine 0.6 mg Filed
Central Nervous System Dimethyl Fumarate 120 mg and 240 mg Under Development
Gastro-Intestinal Esomeprazole 20 mg and 40 mg Filed
Gastro-Intestinal Esomeprazole MG + Naproxen Na 20 mg/375 mg, 20 mg/500 mg Filed
Gastro-Intestinal Lansoprazole ODT 15 mg and 30 mg Filed
Immuno Suppressant Sirolimus 1 mg and 2 mg Filed
Immuno Suppressant Tacrolimus 0.5 mg, 1 mg and 5 mg Filed
Oncology Busulfan 6 mg/ml (10 ml) Filed
Oncology Abiraterone 250 mg and 500 mg Filed
Oncology Imatinib Mesylate 100 mg, 400 mg Filed
Oncology Carmustine 100 mg Filed
Oncology Venetoclax 10 mg, 50 mg and 100 mg Filed
Oncology Sorafenib 200 mg Filed
Oncology Midostaurin 25 mg Filed
Oncology Sunitinib Malate 12.5 mg, 25 mg, 37.5 mg and 50 mg Filed
Oncology Carfilzomib 60 mg Filed
Oncology Nintedanib 100 mg and 150 mg Under Development
Oncology Pazopanib 200 and 400 mg Under Development
Oncology Tofacitinib XR 22 mg Under Development
Oncology Cabozantinib 20 mg, 40 mg and 60 mg Under Development
Oncology Bendamustine RTD 45 mg/ml (4 ml) and 25 mg/ml (4 ml) Filed
Oncology Bortezomib 3.5 mg Filed
Oncology Fingolimod 0.5 mg Filed
Oncology Nano Paclitaxel 100 mg Under Development
Oncology Nilotinib 50, 150 and 200 mg Under Development
Oncology Lenvatinib 4 mg and 10 mg Under Development
Oncology Enzalutamide 40 mg and 80 mg Under Development
Oncology Pazopanib 200 and 400 mg Under Development
Oncology Palbociclib 75, 100 and 125 mg Filed
Oncology Lenalidomide 2.5, 5, 10, 15, 20, 25 mg Filed
Oncology Everolimus 2.5, 5, 7.5, 10 mg Filed
Oncology Dasatinib 20, 50, 70, 80, 100 and 140 mg Filed
Oncology Pomalidomide 1 mg, 2 mg, 3 mg and 4 mg Filed
Oncology Bendamustine 25 and 100 mg Filed
Oncology Azacitidine 100 mg Filed
Oncology Capecitabine 150 mg, 500 mg Filed
Oncology Plerixafor 20 mg/ml (1.2 ml) Filed
Oncology Olaparib 100 mg and 150 mg Under Development
Oncology Pemetrexed 100, 500 and 1 gm Filed
Oncology Palonosetron 0.075 mg/5 ml, 0.25 mg/ 5 ml Filed
Oncology Liposomal Doxorubicin 2 mg/ml (10 ml and 25 ml) Filed
Oncology Fulvestrant 50 mg/ml (5 ml) Filed
Oncology Eribulin 0.5 mg/ml (2 ml) Filed
Oncology Decitabine 50 mg Filed
Oncology Cabazitaxel 40 mg/ml (1.5 ml) Filed
Oncology / Acromegaly Lanreotide 60 mg/0.2 ml, 90 mg/0.3 ml and 120 mg/0.5 ml Under Development
Oncology / Acromegaly Octerotide 10 mg, 20 mg and 30 mg Under Development
Others Teriparatide 0.25 mg/ml (2.4 ml) Filed
Others Isotretinoin 10 mg, 20 mg, 30 mg and 40 mg Filed
Others Valganciclovir 450 mg Filed
Others Mesalamine 250 and 500 mg Under Development
Others Amphotericin B 50 mg Under Development
Others Apremilast 10, 20 and 30 mg Filed
Others Posaconazole 100 mg Filed
Others Naproxen Sodium 275 mg and 550 mg Filed
Others Mesalamine 250 and 500 mg Under Development
Others Amphotericin B 50mg Under Development
Others Ferric Carboxy Maltose 50 mg/ml Under Development
Others Sevelamer Carbonate 800 mg Filed
Others Iron Sucrose 100 mg/5 ml, 200 mg/10 ml and 50 mg/2.5 ml Filed
Others Thiamine 200 mg/2 ml 25's Filed
Others Daptomycin 350 and 500 mg Filed
Therapy Area Product Name Dosage Form EU Approval Status US Approval Status
Immuno Suppressant Fingolimod 0.5 mg Approved Approved
Immuno Suppressant Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg NA Approved
Immuno Suppressant Sirolimus 1 mg and 2 mg NA Approved
Oncology Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials Injection Under review Approved
Oncology Imatinib Mesylate Tablets 100/400 mg NA Approved
Oncology Imatinib Mesylate Capsules 50/100/400 mg Approved NA
Oncology Docetaxel Injection Concentrate and 80 mg/4 ml Injection Approved Approved
Oncology Bendamustine HCl Concentrate for Solution for Infusion 180 mg 4 ml Approved NA
Oncology Bendamustine Hydrochloride Injection 25 mg/Vial and 100 mg/Vial Injection NA Tentative Approved
Oncology Capecitabine Tablets 500 mg Approved Approved
Oncology Capecitabine Tablets 150 mg Oral NA Approved
Oncology Fulvestrant Injection 250 mg/5 ml (50 mg/ml) Injection Approved Approved
Oncology Everolimus 2.5mg, 5mg & 10mg Approved NA
Oncology Dasatinib 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg Film tablet Under review Tentative Approved
Oncology Bortezomib For Injection 3.5 mg/vial Injection Approved Approved
Oncology Decitabine for Injection 50 mglVial Injection NA Approved
Oncology Azacitidine for Inj 100 mg/vial Injection Approved Approved
Oncology Lenalidomide Capsules 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg NA Approved (2.5, 20 mg) Tentative approved (Other SKUs)
Oncology Pemetrexed, 100 mg, 500 mg, powder for concentrate for solution for infusion (Disodium Amorphous) Approved Tentative Approved
Oncology Pemetrexed for Injection 100 mg/vial, 500 mg/vial, 1g/vial Injection NA Tentative Approved
Oncology Pomalidomide Capsules 1 mg, 2 mg, 3 mg and 4 mg NA Tentative Approved
Oncology Carfilzomib for Injection 60 mg/vial Injection NA Approved
Oncology Palbociclib Capsules, 75 mg, 100 mg and 125 mg NA Tentative Approved
Oncology Abiraterone Acetate Tablets 250 mg NA Approved
Oncology Melphalan Hydrochloride for Injection, 50 mg Single-Dose Vial Injection NA Approved
Oncology Cabazitaxel Injection 60 mg/1.5 ml Injection Approved Approved
Oncology Sunitinib Malate Oral NA Approved
Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting
Generic Formulation

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.